Tiziana Life Sciences plc - American Depository Share (TLSA): Price and Financial Metrics
TLSA Price/Volume Stats
| Current price | $1.41 | 52-week high | $1.91 |
| Prev. close | $1.43 | 52-week low | $0.63 |
| Day low | $1.39 | Volume | 157,700 |
| Day high | $1.50 | Avg. volume | 728,508 |
| 50-day MA | $1.25 | Dividend yield | N/A |
| 200-day MA | $1.03 | Market Cap | 164.76M |
TLSA Stock Price Chart Interactive Chart >
Tiziana Life Sciences plc - American Depository Share (TLSA) Company Bio
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.
TLSA Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TLSA Price Returns
| 1-mo | -10.19% |
| 3-mo | -16.57% |
| 6-mo | 39.60% |
| 1-year | 41.00% |
| 3-year | 92.49% |
| 5-year | -39.22% |
| YTD | 102.53% |
| 2024 | 24.32% |
| 2023 | -6.43% |
| 2022 | -37.66% |
| 2021 | -52.48% |
| 2020 | 87.04% |